Indian players must look to deals to grab major share of global biosimilar market, says analyst

While Indian drugmakers have been hugely successful in the generics arena, if they want to succeed in the potentially more lucrative biosimilars sector, they need to look at acquisitions and partnering, a new study reveals.

Biopharmaceuticals accounted for nearly 25% of the global pharmaceutical market revenues from marketed drugs (~$1,100 billion) in 2016. To add to this, the patent expiry of the leading 10 biologic drugs represents a massive $70 billion opportunity for pharma companies over the period 2015-2020.

Against this backdrop, Indian generic pharma players will have to explore mergers and acquisitions (M&As) and alliances to enter new markets and grab a major share in the global biosimilar market, says data and analytics company GlobalData.